Einfach Bitcoin kaufen: Mit dem Code "FINANZEN" sparen Sie 21% der Gebühren für 6 Monate bei Coinfinity. Jetzt loslegen -w-
28.09.2010 12:30:00

MARY ANN GRAY, PH.D., JOINS THE BOARD OF DIRECTORS OF SENOMYX, INC.

Sept. 28, 2010--Senomyx, Inc. (NASDAQ:SNMX), a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Mary Ann Gray, Ph.D., has joined the Company’s Board of Directors. Dr. Gray has extensive experience in both the financial community and the biotechnology industry.

"Mary Ann Gray has a strong background as an equity research analyst, strategic advisor, scientist, and member of Boards of Directors of public companies,” said Kent Snyder, President, Chief Executive Officer, and Chairman of the Board of the Company. "We believe Senomyx will benefit from her insights and expertise as we continue to advance our discovery and development programs and enter into new collaborations with world-class food, beverage, and ingredient supply company partners.”

Mary Ann Gray, Ph.D., is currently President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. Dr. Gray also serves on the Boards of Directors of Dyax Corp. and Acadia Pharmaceuticals, both publicly-held companies, and Apthera Inc., a privately held company. She is the Chairman of the Audit Committee and a member of the Compensation Committee at Acadia, and Lead Director and a member of the Audit Committee at Dyax. During the past five years, Dr. Gray also served on the Boards of Directors of two additional public companies. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody for an aggregate of nine years. Dr. Gray holds a Ph.D. degree in pharmacology from the University of Vermont, where she focused on novel chemotherapeutic agents for the treatment of cancer.

About Senomyx, Inc. (www.senomyx.com)

Senomyx is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. The Company has product discovery and development collaborations with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx’s flavor ingredients. For more information, please visit www.senomyx.com.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Senomyx Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Senomyx Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 19 391,54 0,90%